|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Z: The 3th National Death Cause
Survey Report. Beijing: Chinese Academy of Medical Sciences &
Peking Union Medical College Press; 2008
|
|
4
|
Chen W, Zhang S and Zou X: Evaluation on
the incidence, mortality and tendency of lung cancer in China.
Thoracic Cancer. 1:48–53. 2010. View Article : Google Scholar
|
|
5
|
Chen W, Zheng R, Zeng H and Zhang S: The
Epidemiology of Lung Cancer in China. J Cancer Biol Res.
2:10432014.
|
|
6
|
Guindon GE and Boisclair D: Past, current
and future trend in tobacco. Washington, DC: International Bank for
Reconstruction and Development. The World Bank; pp. 13–16. 2009
|
|
7
|
Cassidy A, Myles JP, van Tongeren M, Page
RD, Liloglou T, Duffy SW and Field JK: The LLP risk model: An
individual risk prediction model for lung cancer. Br J Cancer.
98:270–276. 2008. View Article : Google Scholar
|
|
8
|
Willett WC and Trichopoulos D: Nutrition
and cancer: A summary of the evidence. Cancer Causes Control.
7:178–180. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ruano-Ravina A, Figueiras A and
Barros-Dios JM: Diet and lung cancer: A new approach. Eur J Cancer
Prev. 9:395–400. 2000. View Article : Google Scholar
|
|
10
|
Rudin CM, Avila-Tang E and Samet JM: Lung
cancer in never smokers: A call to action. Clin Cancer Res.
15:5622–5625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Skillrud DM, Offord KP and Miller RD:
Higher risk of lung cancer in chronic obstructive pulmonary
disease. A prospective, matched, controlled study. Ann Intern Med.
105:503–507. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luo RX, Wu B, Yi YN, Huang ZW and Lin RT:
Indoor burning coal air pollution and lung cancer-a case-control
study in Fuzhou, China. Lung Cancer. 14(Suppl 1): S113–S119. 1996.
View Article : Google Scholar
|
|
13
|
Pershagen G: Air pollution and cancer.
IARC Sci Publ. 104:240–251. 1990.PubMed/NCBI
|
|
14
|
Cohen BL: How dangerous is low level
radiation? Risk Anal. 15:645–653. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Devesa SS, Bray F, Vizcaino AP and Parkin
DM: International lung cancer trends by histologic type: Male:
Female differences diminishing and adenocarcinoma rates rising. Int
J Cancer. 117:294–299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morgensztern D, Ng SH, Gao F and Govindan
R: Trends in stage distribution for patients with non-small cell
lung cancer: A National Cancer Database survey. J Thorac Oncol.
5:29–33. 2010. View Article : Google Scholar
|
|
17
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang JC, Schuler MH, Yamamoto N, et al:
LUX-Lung 3: A randomized, open-label, phase III study of afatinib
versus pemetrexed and cisplatin as first-line treatment for
patients with advanced adenocarcinoma of the lung harboring
EGFR-activating mutations. J Clin Oncol. 30(Suppl): Abstract no.
LBA7500. 2012.
|
|
20
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nestler G: Traditional Chinese medicine.
Med Clin North Am. 86:63–73. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu W, Towers AD, Li P and Collet JP:
Traditional Chinese medicine in cancer care: Perspectives and
experiences of patients and professionals in China. Eur J Cancer
Care (Engl). 15:397–403. 2006. View Article : Google Scholar
|
|
23
|
Chikan NA, Bhavaniprasad V, Anbarasu K,
Shabir N and Patel TN: From natural products to drugs for
epimutation computer-aided drug design. Appl Biochem Biotechnol.
170:164–175. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chikan NA and Vipperla B: KAISO
inhibition: An atomic insight. J Biomol Struct Dyn. 33:1794–1804.
2015. View Article : Google Scholar
|
|
25
|
Yun CH, Boggon TJ, Li Y, Woo MS, Greulich
H, Meyerson M and Eck MJ: Structures of lung cancer-derived EGFR
mutants and inhibitor complexes: Mechanism of activation and
insights into differential inhibitor sensitivity. Cancer Cell.
11:217–227. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Trott O and Olson AJ: AutoDock Vina:
Improving the speed and accuracy of docking with a new scoring
function, efficient optimization and multithreading. J comput chem.
31:455–461. 2010.
|
|
27
|
Seeliger D and de Groot BL: Ligand docking
and binding site analysis with PyMOL and Autodock/Vina. J Comput
Aided Mol Des. 24:417–422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Morris GM, Goodsell DS, Halliday RS, Huey
R, Hart WE, Belew RK and Olson AJ: Automated docking using a
Lamarckian genetic algorithm and an empirical binding free energy
function. J Comput Chem. 19:1639–1662. 1998. View Article : Google Scholar
|
|
29
|
Lipinski CA: Lead-and drug-like compounds:
The rule-of-five revolution. Drug Discov Today Technol. 1:337–341.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang QW, Cheng KJ, Mei XL, et al:
Synergistic anticancer effects of triptolide with celastrol, two
main compounds from thunder god vine. Oncotarget. 6:32790–32804.
2015.PubMed/NCBI
|
|
31
|
Meng C, Zhu H, Song H, Wang Z, Huang G, Li
D, Ma Z and Ma J, Qin Q, Sun X and Ma J: Targets and molecular
mechanisms of triptolide in cancer therapy. Chin J Cancer Res.
26:622–626. 2014.PubMed/NCBI
|
|
32
|
Li Y, Shen B, Kim J and Raz D: Triptolide
inhibits Wnt signaling due to DNA methylation alteration that is
determined by dynamic histone 3 K79 lysine methylation in NSCLC.
Cancer Res. 75(15 Suppl): Abstract no. 4777. 2015.
|
|
33
|
Wang G, Xu XS and Zhang Y: The role of
triptolide in sensitizing lung tumor cells to cisplatin-induced
apoptosis. Cancer Res. 74(19 Suppl): Abstract no. 5110. 2014.
|
|
34
|
Ma L, Wen S, Zhan Y, He Y, Liu X and Jiang
J: Anticancer effects of the Chinese medicine matrine on murine
hepatocellular carcinoma cells. Planta Med. 74:245–251. 2008.
View Article : Google Scholar : PubMed/NCBI
|
